Markets
← Back to Stocks
VRTX
VERTEX PHARMACEUTICALS INC
Health Care · Biotechnology
$458.03
+1.43%
Vol: 0.0M
Araverus Market Read
Thursday, March 19, 2026
Maxim Buy upgrade on povetacicept blockbuster potential powers Vertex analyst optimism weigh on near-term
Vertex Pharmaceuticals received Buy upgrade from Maxim with $575 price target citing blockbuster potential and pipeline-in-a-product opportunity for povetacicept. Pre-market shows $462.60 down 0.02% and after-hours $463.80 down 0.28%, with stock down $3.24 (-0.69%) since previous close before modest after-hours recovery. Analyst confidence in pipeline depth supports longer-term growth thesis.
Price 50d 200d
Previous Market Reads
2 of 2 daysSector Peers
| Company | Price | Day | 1M | Fwd P/E | Beta | Mkt Cap |
|---|---|---|---|---|---|---|
| LLYELI | $916.83 | -0.13% | -11.4% | 21.8x | 0.43 | $821.2B |
| JNJJOHNSON | $237.56 | +0.16% | -1.8% | 18.9x | 0.33 | $572.6B |
| ABBVABBVIE | $206.31 | -0.97% | -11.4% | 12.8x | 0.33 | $364.6B |
| MRKMERCK | $114.17 | -0.29% | -5.4% | 11.7x | 0.26 | $282.3B |
| UNHUNITEDHEALTH | $280.37 | -1.29% | -2.2% | 14.1x | 0.38 | $254.5B |
| AMGNAMGEN | $349.90 | -0.42% | -6.3% | 15.0x | 0.42 | $188.6B |
| ABTABBOTT | $107.19 | -1.12% | -4.5% | 17.2x | 0.74 | $186.3B |
| GILDGILEAD | $141.06 | -0.17% | -8.6% | 14.7x | 0.37 | $175.2B |
| TMOTHERMO | $470.21 | +1.18% | -6.2% | 17.5x | 0.97 | $174.7B |
Fundamentals
Market Cap$116.3B
P/E (TTM)29.9
Forward P/E20.9
Beta0.32
Div Yield—
Prev Close$451.59
RSI (14-Day)
37Neutral
0305070100
52-Week Range
$362.50$458.03$515.67
From High-11.2%
From Low+26.4%
Moving Averages
50d SMA
$469.79-2.5%
200d SMA
$438.48+4.5%
Price between 50d and 200d. Testing 50d support.
Returns
1W
-4.2%
1M
-2.6%
3M
+0.7%
6M
+18.3%
1Y
-10.6%
YTD
+1.3%
Volume
Today30K
20d Avg1.4M
Ratio0.02x